Chemically specific imaging of tissue

• US 6,503,478 B2
• Filed: 01/13/2000
• Issued: 01/07/2003
• Est. Priority Date: 01/13/1999
• Status: Expired due to Fees

• Current Assignee: Lightouch Medical, Inc.
• Original Assignee: Lightouch Medical, Inc.
• Inventors: Chaiken, Joseph, Peterson, Charles M.
• Primary Examiner(s): JONES, DAMERON LEVEST
• Application Number:
  US09/482,413
• Publication Number:
  US 20020041848A1
• Time in Patent Office: 1,090 Days
• Field of Search: 424/1.11, 424/1.49, 424/1.61, 424/1.65, 424/9.1, 423/644, 356/300, 356/301
• US Class Current: 424/9.1
• CPC Class Codes: A61K 49/16 Antibodies; Immunoglobulins; Fragments thereof
• CPC Class Codes: G01N 21/65 Raman scattering

Abstract

Disclosed are methods and materials for obtaining spatially resolved images of specific types of tissues. The method for imaging tissue comprises administering to the tissue a deuterated imaging agent and performing spectroscopy, preferably Raman spectroscopy. Electromagnetic radiation, such as a near infrared laser beam, is directed to a tissue of interest. The radiation can be scanned across and within the tissue of interest. When used in combination with a light collection system, it is possible to map out a specific volume of tissue, obtaining information regarding the distribution of specific endogenous chemical species. In some embodiments, specific imaging agents are employed to impart contrast between chemically different types of tissues.

Claims

1. A method for imaging tissue comprising:

(a) administering to the tissue a deuterated imaging agent;

(b) irradiating the tissue with a source of electromagnetic radiation; and

(c) collecting and analyzing Raman spectra emitted from the tissue.

2. The method of claim 1, wherein the deuterated imaging agent comprises an agent that specifically recognizes and binds a target tissue.

3. The method of claim 2, wherein the deuterated imaging agent comprises an antibody or fragment thereof.

4. The method of claim 1, wherein the deuterated imaging agent comprises a highly penetrating deuterated imaging agent.

5. The method of claim 4, wherein the deuterated imaging agent is sufficiently penetrating so as to enhance imaging of voids, such that the agent is detectable in voids after two or more washes.

6. The method of claim 4, wherein the deuterated imaging agent is sufficiently penetrating so as to enhance imaging of densified regions, such that the agent is detectable in densified regions after two or more washes.

7. The method of claim 1, wherein the deuterated imaging agent is capable of selectively penetrating the tissue so as to enhance imaging of a target tissue, such that the agent is detectable in the target tissue after two or more washes.

8. The method of claim 1, wherein the deuterated imaging agent comprises an agent selected from the group consisting of water, phospholipids, alkyl esters, alkyl alcohols, fatty acids, urea and pyrrolidones.

9. The method of claim 1, wherein the deuterated imaging agent comprises an agent selected from the group consisting of partially deuterated and perdeutero-{stearic acid, palmitic acid, linoleic acid, oleic acid, mono-, di-and tri-glycerides, glycerol, cholesterol, propylene glycol, 1-8 cineol, 2-n-nonyl- 1,3-dioxolane), 1-dodecylazacycloheptan-2-one, 4-decycloxazolidin-2-one, sphinganine, 4-hydroxysphinganine, N-acetylated sphinganine and 4-hydroxysphinganine}.

10. The method of claim 1, wherein the analyzing comprises determining a surface fractal dimension of a portion of the tissue having an area and a perimeter.

11. The method of claim 10, wherein the determining of a surface fractal dimension comprises dividing the area of the portion of tissue by the perimeter of the portion of tissue.

12. The method of claim 10, wherein the portion of tissue comprises a cell, a mass of cells or a tumor.

13. The method of claim 10, wherein the surface fractal dimension is derived from first and second iterations of steps (b) and (c) performed with first and second regions of the tissue, respectively, wherein the first region of the tissue comprises a portion of the second region of the tissue.

14. The method of claim 13, wherein the analyzing of step (c) further comprises determining a slope of a line connecting first and second points, wherein the first point is a logarithm of total Raman spectra emitted by the first region of the tissue plotted as a function of a logarithm of area of the first region of the tissue, and the second point is a logarithm of total Raman spectra emitted by the second region of the tissue plotted as a function of a logarithm of area of the second region of the tissue.

15. The method of claim 1, wherein the tissue is living tissue or an excised specimen of tissue.

16. The method of claim 1, that is noninvasive.

17. The method of claim 1, wherein the tissue is human tissue.

39. The method of claim 1, wherein the tissue comprises skin.

18. A diagnostic composition for use with Raman spectroscopic imaging comprising a deuterated imaging agent selected from the group consisting of phospholipids, alkyl esters, alkyl alcohols, and urea, and a pharmaceutically acceptable carrier.

19. The diagnostic composition of claim 18 wherein the deuterated imaging agent is selected from the group consisting of partially deuterated and perdeutero-linoleic acid, oleic acid, mono-, di- and tri-glycerides, glycerol, cholesterol, propylene glycol, 1-8 cineol, 2-n-,nonyl-1,3-dioxolane), 1-dodecylcazacyleoheptan-2-one, 4-decycloxazolidin-2-one, sphinganine, 4-hydroxysphinganine, N-acetylated sphinganine and 4-hydroxysphinganine}.

20. A nonradioactive diagnostic composition for use with Raman spectroscopic imaging comprising a deuterated antibody or fragment thereof.

21. A method for imaging tissue comprising:

(a) administering to the tissue a deuterated imaging agent;

(b) irradiating the tissue with a source of electromagnetic radiation; and

(c) collecting and analyzing spectra emitted from the tissue

wherein the analyzing comprises determining a surface fractal dimension of a portion of the tissue having an area and a perimeter.

22. The method of claim 21, wherein the deuterated imaging agent comprises an agent that specifically recognizes and binds a target tissue.

23. The method of claim 22, wherein the deuterated imaging agent comprises an antibody or fragment thereof.

24. The method of claim 21, wherein the deuterated imaging agent comprises a highly penetrating deuterated imaging agent.

25. The method of claim 24, wherein the deuterated imaging agent is sufficiently penetrating so as to enhance imaging of voids, such that the agent is detectable in voids after two or more washes.

26. The method of claim 24, wherein the deuterated imaging agent is sufficiently penetrating so as to enhance imaging of densified regions, such that the agent is detectable in densified regions after two or more washes.

29. The method of claim 21, wherein the deuterated imaging agent comprises an agent selected from the group consisting of partially deuterated and perdeutero-{stearic acid, palmitic acid, linoleic acid, oleic acid, mono-, di-and tri-glycerides, glycerol, cholesterol, propylene glycol, 1-8 cineol, 2-n-nonyl-1,3-dioxolane), 1-dodecylazacycloheptan-2-one, 4-decycloxazolidin-2-one, sphinganine, 4-hydroxysphinganine, N-acetylated sphinganine and 4-hydroxysphingariune}.

30. The method of claim 21, wherein the determining of a surface fractal dimension comprises dividing the area of the portion of tissue by the perimeter of the portion of tissue.

31. The method of claim 21 wherein the portion of tissue comprises a cell, a mass of cells or a tumor.

32. The method of claim 21, wherein the surface fractal dimension is derived from first and second iterations of steps (b) and (c) performed with first and second regions of the tissue, respectively, wherein the first region of the tissue comprises a portion of the second region of the tissue.

33. The method of claim 32, wherein the analyzing of step (c) further comprises determining a slope of a line connecting first and second points, wherein the first point is a logarithm of total Raman spectra emitted by the first region of the tissue plotted as a function of a logarithm of area of the first region of the tissue, and the second point is a logarithm of total Raman spectra emitted by the second region of the tissue plotted as a function of a logarithm of area of the second region of the tissue.

34. The method of claim 21, wherein the tissue is living tissue or an excised specimen of tissue.

35. The method of claim 21, that is noninvasive.

36. The method of claim 21, wherein the tissue is human tissue.

40. The method of claim 21, wherein tissue comprises skin.

27. The method of claim wherein 21, the deuterated imaging agent is capable of selectively penetrating the tissue so as to enhance imaging of a target tissue.

28. The method of claim wherein the deuterated imaging agent comprises an agent selected from the group consisting of water, phospholipids, alkyl esters, alkyl alcohols, fatty acids, urea and pyrrolidones.

37. A diagnostic composition for use with Raman spectroscopic imaging consisting essentially of a deuterated imaging agent selected from the group consisting of phospholipids, alkyl esters, alkyl alcohols, and urea, and a pharmaceutically acceptable carrier.

38. The diagnostic composition of claim 37, wherein the deuterated imaging agent is selected from the group consisting of partially deuterated and perdeutero-{linoleic acid, oleic acid, mono-, di-and tri-glycerides, glycerol, cholesterol, propylene glycol, 1-8 cineol, 2-n-nonyl-1,3-dioxolane), 1-dodecylcazacyleoheptan-2-one, 4-decycloxazolidin-2-one, sphinganine, 4-hydroxysphinganine, N-acetylated sphinganine and 4-hydroxysphinganine}.